rate with the result likely to be achieved.

(d) The exclusion criteria adopted by Kelkar Committee are given in reply to Rajya Sabha unstarred Question No 1565 for 8-8-1988. These were accepted by the Government

(f) Sales turnover is not monitored.

Manufacture of Scheduled Formulations

1558. DR. BAPU KALDATE: Will the Minister of INDUSTRY be pleased to refer to the answer to Unstarred Question No. 1397 given in the Rajya Sabha on the 9th May, 1988 and state:

(a) what are the names of scheduled formulations manufactured by SSI Units being marketed by M/s Warner Hindustan, M/s. Hoechst and M|s. Merind Limited. M|s Glindia, German Remedies, Infar, Pfizer and Parke Davis:

(b) the composition of each formulation the price fixed for each product. and the price at which each formulation is being sold by these companies:

(c) the price of bulk drug taken while fixing price each formulation and when was the price of each formulation fixed by his Ministry;

(d) the names of bulk drugs based on which each of these formulations is produced. how many of these bulk drugs are under price control and are produced in the country:

(e) the names of producers stage of production of each along with production of each during the last three years, year-wise; and

(f) names of bulk drugs being imported along with the details of imports of each during the last two years, year-wise?

THE MINISTER OF INDUSTRY (SHRI J. VENGAL RAO): (a) to (f) To the extent information is available M/s Parke Davis and Warner Hindustan are presently not marketing any scheduled formulations produced by SSI units. The required details in respect of the other companies referred to in the question are quite voluminous and are not readily available. Time and efforts required for collection of the same will not be commensurate with the results likely to be achieved.

Production stages of drugs

1559. SHRI M. KADHARSHA: Will the Minister of INDUSTRY be pleased to state:

(a) whether it is a fact that his Ministry has allowed phased manufacturing in respect of drugs being produced in the country from intermediate and penultimate stages;

(b) if so, what are the names of those drugs along with the details of period allowed in each case;

(c) whether it is a fact that his Ministry has allowed further extension in certain cases;

(d) if so, what are the details thereof; and

(e) by when each of these drugs will be produced from basic stages in the country?

THE MINISTER OF INDUSTRY (SHRI J. VENGAL RAO): (a) Yes, Sir.

(b) Drugs for which PMP has been prescribed are those where technology for basic production is not readily available indigenously.

(c) to (e) Considering technological constraints, extensions are allowed for the minimum period required.

Prices of Formulations

1560. DR. (SHRIMATI) NAJMA HEPTULLA: Will the Minister of INDUSTRY be pleased to state:

(a) what are tht names of formulations the prices of which have been increased under DPCO 1987 without

any change in make/mark up and the notified price of the bulk drug;

(b) whether such increase has been allowed and based on addition of incidental costs which were not allowed earlier as the market price of the drugs involved was lower than the notified price;

(c) if so, what necessitated the reversal of the decision; and

(d) what is the locus standi of the Drug Prices Review Committee and to whom it is responsible?

THE MINISTER OF INDUSTRY (SHRI J. VENGALRAO): (a) to (c) Prices of a large number of formulations have been fixed/revised as per provisions of DPCO, 1987. Prices of Scheduled formulations depend on several factors in addition to the rate of MAPE and prices of bulk drug concerned, including incidental charges.

(d) The Drug Prices Review Committee is an interministerial Committee which sends its recommndations to the Deptt. of Chemicals and Petro-Chemicals in the Ministry of Industry.

Submission of details of Imports of Drug Intermediates

1561. DR. (SHRIMATI) NAJMA HEPTULLA: Will the Minister of INDUSTRY be pleased to state:

(a) whether it is a fact that as per provision 6.7 of measures 1986, all existing drug companies which import drug intermediates and other raw materials from their principals or their associated companies are required to submit the details of such transactions within a period of one month of such imports;

(b) if so, what are the names of the drug companies alongwith names of intermediates and other raw materials imported from their principals and associated companies during 1987;

(c) whether it is a fact that in a number of cases, there is over invoicing and transfer of pricing; and

(d) if so, what system has been evolved by his Ministry to check, monitor and scrutinise such cases?

THE MINISTER OF INDUSTRY (SHRI J. VENGAL RAO): (a) Yes, Sir.

(b) to (c) No company has furnished any such transaction so far.

(d) Department of Chemicals and Petrochemicals scrutinise the details available in this regard.

Composition of monitoring cell for drug prices

1562. DR. (SHRIMATI) NAJMA HEPTULLA: Will the Minister of INDUSTRY be pleased to refer to the answer to Unstarred Question 1358 given in the Rajya Sabha on the 9th May, 1988 and state:

(a) how many persons have been appointed in the monitoring cell to monitor the prices of drugs and what functions have been assigned to them;

(a) what are the names of the medicines in the decontrolled category the prices of which have been communicated to the cell and what were the prices of such medicines under DPCO, 1978;

(c) what were the prices of price-decontrolled antidiabeties cough syrups, ATS and vitamin preparation products by leading manufacturers under DPCO, 1979 and at present; and

(d) what are the areas covered by the monitoring cell and whether it is a fact that details of sales turnover are given by the manufacturers in their price revision applications?

THE MINISTER OF INDUSTRY (SHRI J. VENGAL RAO): (a) Three officials have been appointed in the